Fidelity Investments
GMAB icon

Fidelity Investments’s Genmab GMAB Stock Holding History

Fidelity Investments’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Sell
764,694
-247,032
-24% -$6.57M ﹤0.01% 1865
2026
Q1 		$27.1M Sell
1,011,726
-45,614
-4% -$1.37M ﹤0.01% 1662
2025
Q4 		$32.6M Sell
1,057,340
-62,374
-6% -$1.94M ﹤0.01% 1596
2025
Q3 		$34.3M Buy
1,119,714
+439,181
+65% +$10.7M ﹤0.01% 1585
2025
Q2 		$14.1M Buy
680,533
+195,687
+40% +$4.02M ﹤0.01% 1802
2025
Q1 		$9.49M Sell
484,846
-55,707
-10% -$1.17M ﹤0.01% 1936
2024
Q4 		$11.3M Buy
540,553
+262,359
+94% +$5.76M ﹤0.01% 1900
2024
Q3 		$6.78M Buy
278,194
+33,076
+13% +$884K ﹤0.01% 2050
2024
Q2 		$6.16M Sell
245,118
-129,289
-35% -$3.67M ﹤0.01% 2016
2024
Q1 		$11.2M Buy
374,407
+106,902
+40% +$3.14M ﹤0.01% 1836
2023
Q4 		$8.52M Sell
267,505
-154,932
-37% -$4.86M ﹤0.01% 1898
2023
Q3 		$14.9M Buy
422,437
+24,936
+6% +$950K ﹤0.01% 1698
2023
Q2 		$15.1M Buy
397,501
+6,090
+2% +$243K ﹤0.01% 1743
2023
Q1 		$14.8M Sell
391,411
-60,248
-13% -$2.32M ﹤0.01% 1737
2022
Q4 		$19.1M Buy
451,659
+14,661
+3% +$604K ﹤0.01% 1629
2022
Q3 		$14M Buy
436,998
+191,071
+78% +$6.71M ﹤0.01% 1754
2022
Q2 		$7.99M Buy
245,927
+25,320
+11% +$820K ﹤0.01% 2074
2022
Q1 		$7.98M Buy
220,607
+67,258
+44% +$2.31M ﹤0.01% 2210
2021
Q4 		$6.07M Buy
153,349
+21,459
+16% +$895K ﹤0.01% 2303
2021
Q3 		$5.76M Buy
131,890
+19,300
+17% +$866K ﹤0.01% 2316
2021
Q2 		$4.6M Sell
112,590
-59,812
-35% -$2.31M ﹤0.01% 2353
2021
Q1 		$5.66M Buy
172,402
+88,934
+107% +$3.34M ﹤0.01% 2220
2020
Q4 		$3.39M Sell
83,468
-169,255
-67% -$6.33M ﹤0.01% 2283
2020
Q3 		$9.25M Buy
252,723
+235,503
+1,368% +$8.51M ﹤0.01% 1856
2020
Q2 		$584K Buy
17,220
+8,589
+100% +$234K ﹤0.01% 2490
2020
Q1 		$183K Buy
8,631
+3,906
+83% +$87.1K ﹤0.01% 2583
2019
Q4 		$106K Buy
4,725
+2,858
+153% +$62.4K ﹤0.01% 2744
2019
Q3 		$38K Buy
+1,867
New +$36.8K ﹤0.01% 2921

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments's GMAB Position: Q2 2026 in Review

Fidelity Investments reduced its Genmab (GMAB) stake by 24% in Q2 2026, selling an estimated $6.57M and leaving 764,694 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Fidelity Investments first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $34.3M in Q3 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Fidelity Investments held 764,694 shares of Genmab worth $21M as of Q2 2026.
  • Fidelity Investments sold 247,032 Genmab shares in Q2 2026, an estimated $6.57M.
  • Genmab made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1865 holding.
  • Fidelity Investments first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Fidelity Investments's Genmab position peaked at $34.3M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.